ENLIVEX THERAPEUTICS LTD
(NASDAQ: ENLV)

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

3.750

-0.110 (-2.85%)
Range - - -   (-%)
Open -
Previous Close 3.860
Bid Price 2.660
Bid Volume 10
Ask Price 2.900
Ask Volume 12
Volume 64,052
Value -
Remark
Delayed prices. Updated at 28 Mar 2024 22:29.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis